Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Quetiapine - efficacy in different domains
Autore:
Sharma, T;
Indirizzi:
Stonehouse Hosp, Clin Neurosci Res Ctr, Dartford DA2 6AU, Kent, England Stonehouse Hosp Dartford Kent England DA2 6AU ford DA2 6AU, Kent, England
Titolo Testata:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
, volume: 11, anno: 2001, supplemento:, 4
pagine: 385 - 390
SICI:
0924-977X(200110)11:<385:Q-EIDD>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROPSYCHOLOGICAL FUNCTION; SCHIZOPHRENIC PATIENTS; DEFICITS; IMPAIRMENT; PLACEBO;
Keywords:
atypical antipsychotic; quetiapine; clinical efficacy; cognitive function; tolerability;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Sharma, T Stonehouse Hosp, Clin Neurosci Res Ctr, Cotton Lane, Dartford DA2 6AU, Kent, England Stonehouse Hosp Cotton Lane Dartford Kent England DA2 6AU ngland
Citazione:
T. Sharma, "Quetiapine - efficacy in different domains", EUR NEUROPS, 11, 2001, pp. 385-390

Abstract

Conventional treatment paradigms for schizophrenia have typically focused on reducing positive symptomatology; however, it is increasingly apparent that negative and cognitive symptoms are also important treatment targets. Cognitive function, in particular, is known to affect multiple outcome domains, including performance of basic daily activities, and social and occupational functioning. While traditional antipsychotics have little, or even a detrimental, effect on neurocognitive impairment in patients with schizophrenia, available data suggest that cognitive function may be improved duringtreatment with atypical antipsychotics. Quetiapine is a novel atypical antipsychotic with proven efficacy in schizophrenia across all domains. Results of well-controlled, double-blind, randomised studies show quetiapine to significantly improve cognitive function compared with treatment with haloperidol. Quetiapine has also been shown to be effective and well tolerated inpatients particularly vulnerable to the extrapyramidal side effects (EPS) associated with conventional antipsychotics, making it well suited for use as first-line therapy. (C) 2001 Elsevier Science BY. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/12/19 alle ore 11:47:00